Both in Pharmaceuticals
CytomX Therapeutics vs Monopar Therapeutics
Over the past year CTMX returned −28.9% and MNPR returned −8.2%; their daily moves had a correlation of 0.30.
CTMX −28.9% MNPR −8.2%Growth of $1, one year, split-adjusted
| Metric | CTMX | MNPR |
|---|---|---|
| Price | $2.36 | $73.39 |
| Market cap | $514.2M | $492.6M |
| Today | +2.16% | +2.16% |
| 1 month | −14.2% | −8.3% |
| 6 months | −41.7% | +46.4% |
| Year to date | −44.6% | +12.4% |
| 1 year | −29.8% | −9.7% |
| Revenue growth (YoY) | −92.4% | — |
| Gross margin | 100.0% | — |
| Net margin | −1457.4% | — |
| P/E (TTM) | — | — |
| Price / sales | 28.1× | — |
| Net cash | $330.3M | $134.3M |
| Dividend yield | — | — |
| Volatility (60d) | 67.0% | 49.2% |
| Short % of float | 21.4% | 23.3% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).